| Detected | Trial | Change |
|---|---|---|
| 2026-05-16 | NCT04524273 Myasthenia Gravis Inebilizumab Trial |
date change Completion pushed: 2027-11-29 -> 2029-06-07 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-20 | NCT07598825 A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07010302 | Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD | NMOSD | Not Yet Recruiting |
| Phase 3 | |||
| NCT04524273 | Myasthenia Gravis Inebilizumab Trial | Myasthenia Gravis | Active, Not Recruiting |
| NCT07598825 | A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | Autoimmune Hepatitis | Not Yet Recruiting |
| Phase 2 | |||
| NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Systemic Lupus Erythematosus | Recruiting |
| NCT06987539 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of… | Generalized Myasthenia Gravis | Recruiting |
| NCT07222553 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of… | Immunoglobulin G4-related Disease | Not Yet Recruiting |
| Not specified | |||
| NCT05909761 | Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD)… | Neuromyelitis Optica Spectrum Disorder | Recruiting |